Kenvue (NYSE:KVUE) Price Target Cut to $20.00

Kenvue (NYSE:KVUE) had its price objective cut by analysts at Citigroup from $21.00 to $20.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Citigroup’s price target would suggest a potential upside of 11.61% from the company’s previous close.

Several other analysts also recently commented on the company. Sanford C. Bernstein started coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective for the company. HSBC increased their price objective on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research note on Wednesday, May 8th. Finally, William Blair started coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $23.00.

Kenvue Stock Up 1.2 %

KVUE stock opened at $17.92 on Wednesday. The stock’s 50 day simple moving average is $19.02 and its 200 day simple moving average is $19.80. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $25.61. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. The company has a market cap of $34.31 billion, a P/E ratio of 22.97, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The business had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. Kenvue’s revenue for the quarter was down 24.9% on a year-over-year basis. On average, research analysts expect that Kenvue will post 1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kenvue

Several institutional investors and hedge funds have recently bought and sold shares of the company. Beaumont Financial Advisors LLC boosted its holdings in shares of Kenvue by 3.0% in the fourth quarter. Beaumont Financial Advisors LLC now owns 17,532 shares of the company’s stock worth $377,000 after acquiring an additional 509 shares during the period. Pinnacle Bancorp Inc. boosted its holdings in shares of Kenvue by 51.3% in the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock worth $33,000 after acquiring an additional 526 shares during the period. Manchester Capital Management LLC boosted its holdings in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after acquiring an additional 530 shares during the period. Tradition Wealth Management LLC boosted its holdings in shares of Kenvue by 2.8% in the fourth quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock worth $458,000 after acquiring an additional 575 shares during the period. Finally, Dfpg Investments LLC boosted its holdings in shares of Kenvue by 2.3% in the fourth quarter. Dfpg Investments LLC now owns 26,659 shares of the company’s stock worth $567,000 after acquiring an additional 589 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.